Riskpilot← Back to searchSign inGet full accessLindbom Pharmacometric Consulting AB
ABActiveOrg 5568322142Åsbranten 34Business and other management consultancy activities · NACE 7020Est. 20100 employees
Revenue 2024
SEK 4,7M
-71% vs 2023
EBITDA margin
92.5%
+31% vs 2023
Equity ratio
53.7%
Financial strength
Net profit 2024
SEK 2,9M
-2% vs 2023
| Revenue | SEK 4,7M | -71% |
| EBITDA | SEK 4,3M | +31% |
| Net profit | SEK 2,9M | -2% |
| Total assets | SEK 14,1M | -9% |
| Equity | SEK 7,6M | -2% |
| Employees | 0 | — |
Legal name
Lindbom Pharmacometric Consulting AB
Org number
5568322142
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
14 december 2010
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska tillhandahålla nationella och internationella konsulttjänster inom läkemedelsbranschen samt bedriva därmed förenlig verksamhet.
Address
Åsbranten 34
Email
lindbom@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 10 501 | 11 551 | 15 372 | 16 433 | 4 694 |
| Staff expenses | — | — | — | −10 871 | −270 |
| EBITDA | 3 263 | 3 515 | 5 712 | 3 316 | 4 344 |
| Depreciation & amort. | −7 | −3 | −0 | −2 | −10 |
| EBIT | 3 256 | 3 512 | 5 712 | 3 315 | 4 334 |
| Net financials | 31 | 196 | 513 | −11 | 542 |
| Profit before tax | 2 877 | 2 771 | 4 725 | 3 933 | 3 718 |
| Tax | −647 | −644 | −998 | −983 | −840 |
| Net profit | 2 230 | 2 127 | 3 727 | 2 951 | 2 878 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 7 459 | 10 886 | 16 363 | 15 463 | 14 084 |
| Equity | 2 875 | 5 002 | 7 729 | 7 680 | 7 557 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 2 460 | 2 824 | 4 074 | 3 854 | 1 438 |
| Total debt | 2 460 | 2 824 | 4 074 | 3 854 | 1 438 |
EBITDA margin
92.5%
This company
15.8%
Market median
+485% vs market
20202024
Equity ratio
53.7%
This company
38.2%
Market median
+41% vs market
20202024
Return on equity
38.1%
This company
18.4%
Market median
+107% vs market
20202024
Net profit margin
61.3%
This company
8.1%
Market median
+657% vs market
20202024
Asset turnover
0.33×
This company
1.12×
Market median
-71% vs market
20202024
Debt / equity
0.86×
This company
0.62×
Market median
+39% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AM Chief Auditor | Chief Auditor | 2022 |
LS Chief Executive Officer | Chief Executive Officer | 2021 |
| Former (1) | ||
SE Chief Auditor | Chief Auditor | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Lindbom Pharmacometric Consulting AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Serhat Eliacik | Chief Auditor | 0 companies |
| Andreas Mattias Gröndahl | Chief Auditor | 0 companies |
| Lars Sture Lindbom | Chief Executive Officer | 0 companies |
| Maria Helena Tunblad | Deputy Board Member | 0 companies |